Overview of Calperos D3

Property	Description
Active Ingredients	Calcium carbonate and Cholecalciferol (Vitamin D3)
Form	Chewable Tablet / Oral Dosage Form
Pharmacological Class	Vitamin and Mineral Combination (ATC A12AX)
General Purpose	Correcting concurrent Calcium and Vitamin D Deficiencies
Origin	Combination of Mineral Salt and Prohormone Analog

1. Defining Calperos D3: Classification and Identity

Calperos D3 is formally defined as a fixed-dose combination pharmacological preparation, utilizing an oral dosage form presented as a chewable tablet. It is categorized as a vitamin and mineral combination product, specifically grouped with Calcium in association with vitamin D and/or other substances (ATC A12AX). This combination formulation is clinically recognized for its intended role in maintaining healthy bone and mineral metabolism. Unlike standard calcium tablets, Calperos D3 is specifically designed as a chewable format, addressing patient preference and enhancing accessibility, particularly for elderly subjects.

2. Active Ingredients and Composition

The active core of Calperos D3 consists of the mineral source Calcium carbonate and the prohormone Cholecalciferol (the chemical name for Vitamin D3). Calcium carbonate is an inorganic mineral salt that provides the necessary elemental calcium. Cholecalciferol is a vital fat-soluble vitamin analog. For example, similar formulations are often recommended in supplemental care regimens for patients with postmenopausal osteoporosis. The use of the highly bioavailable calcium carbonate salt further supports the rapid availability of the mineral after ingestion.

3. General Therapeutic Purpose

The overall purpose of Calperos D3 is to effectively manage or prevent concurrent shortfalls of calcium and Vitamin D within the body. The dual-component mechanism is aimed at maintaining structural integrity and physiological function. Vitamin D is necessary for the gut to absorb calcium. This fundamental action ensures the supplied elemental calcium contributes directly to bone mineral density and supports stable serum calcium levels required for nerve and muscle signaling. The combination of ingredients is crucial for supporting overall mineral homeostasis.

Regulatory References

What side effects are possible with Calperos D3?

Possible Side Effects and Safety Information

The safety profile of Calperos D3, which contains calcium and cholecalciferol (Vitamin D3), is defined by its potential to affect calcium levels in the body, as documented in regulatory sources.

Adverse Reactions

Adverse reactions are classified by frequency according to the standard regulatory convention:

Uncommon (affecting 1 to 10 users in 1,000): Hypercalcaemia (high blood calcium levels) and Hypercalciuria (high urine calcium levels). These represent the central metabolic risk associated with the drug.
Rare (affecting 1 to 10 users in 10,000): Reactions involving the gastrointestinal and skin systems, including nausea, vomiting, diarrhoea, constipation, flatulence, pruritus (itching), rash, and urticaria (hives).
Not Known (cannot be estimated from available data): Hypersensitivity reactions (allergic reactions), including serious forms such as anaphylactic reaction or angioedema.

Safety Restrictions and Monitoring

Contraindications (Situations where the drug must not be used): The medicine is officially contraindicated in individuals with hypercalcaemia, hypercalciuria, nephrolithiasis (kidney stones), severe renal failure, hypervitaminosis D (excess Vitamin D), or a known hypersensitivity to the product's components.

Population-Specific Precautions: Official safety information requires caution and monitoring of calcium levels in both the blood and urine when used in patients with renal insufficiency or those with a history of kidney stones.

Dose-Related Patterns: The risk of developing hypercalcaemia and hypercalciuria is associated with the use of high doses or long-term treatment. Therefore, periodic monitoring of calcium levels is required for patients receiving extended treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Calperos D3 (Calcium Carbonate and Cholecalciferol) results in the documented clinical states of Hypercalcaemia and Hypervitaminosis D, based on regulatory information. The severity of toxicity ranges from mild symptomatic presentations to extreme hypercalcaemia, which regulators define as a potentially life-threatening condition.

Documented Manifestations and Severe Outcomes

Symptoms of overdose may include systemic and gastrointestinal signs such as anorexia, persistent thirst (polydipsia), nausea, vomiting, constipation, muscle weakness, fatigue, and mental disturbances. Overdose affects the renal system, potentially leading to irreversible renal damage, nephrocalcinosis, and polyuria. In severe cases, official labeling notes the risk of cardiac arrhythmias, and extreme hypercalcaemia may progress to coma and death.

Required Emergency Actions

Immediate medical attention is required if an overdose is suspected or if persistent symptoms of toxicity are present. The first official management step is the discontinuation of the calcium and vitamin D treatment. Treatment is defined as entirely symptomatic and supportive. Severe cases mandate specific interventions, including rehydration, monitoring of serum electrolytes, renal function, and, in the most severe instances, ECG monitoring. Overdose in pregnant women must be strictly avoided due to documented risks of adverse effects on the developing foetus.

Therapeutic Uses of Calperos D3

Therapeutic Uses and Benefits

Calperos D3 is a fixed-dose combination medicinal product containing calcium carbonate and cholecalciferol (vitamin D3). It is primarily used to address physiological and metabolic conditions where both calcium and vitamin D levels require supplementation.

Primary Indications

Correction of Combined Deficiencies: The medication is indicated for the correction of concurrent vitamin D and calcium deficiencies in elderly patients.
Supportive Therapy for Osteoporosis: It is used as a supplement to specific treatments for osteoporosis in patients who are at risk of combined vitamin D and calcium deficiency.

Mechanism and Benefits

Calcium Homeostasis

Calcium is a vital mineral essential for the maintenance of the skeletal system, nervous system signaling, and muscle function. In the context of bone health, calcium provides the structural integrity necessary for bone density. Supplementation helps ensure that the body has an adequate supply of this mineral, reducing the need for the body to resorb calcium from bone tissue.

Vitamin D3 Integration

Cholecalciferol (vitamin D3) plays a critical role in the intestinal absorption of calcium and the regulation of calcium metabolism. By including vitamin D3, the formulation enhances the biological availability of the co-administered calcium. It also supports the process of bone mineralization.

Skeletal Preservation

The combination of these two components is intended to help maintain bone mass and reduce the rate of bone loss associated with aging or specific metabolic conditions. By stabilizing calcium levels, the therapy supports the overall strength and resilience of the skeletal structure.

Eligibility and Restrictions for Use

Who can and cannot use Calperos D3?

The official eligibility profile for Calperos D3 (Calcium carbonate and Cholecalciferol) is based on a strict set of regulatory rules to prevent toxicity and manage metabolic risk.

Scope	Regulatory Statement
Populations for whom use is allowed	Adults and Elderly are the standard eligible groups. Use in adolescents is restricted by a minimum age threshold, often 18 years in many regulatory labels for this product.
Populations for whom use is contraindicated	Patients with Hypercalcaemia (high calcium levels), Hypercalciuria, Hypervitaminosis D, Nephrolithiasis (kidney stones), or Severe Renal Impairment must not use the medicine.
Pregnancy and Lactation Eligibility	Use is permitted but is strictly restricted to specific low daily dose limits, requiring medical supervision to avoid maternal or fetal toxicity risks.
Eligibility-related Restrictions	Caution and close monitoring of calcium levels are required for patients with Mild-to-Moderate Renal Impairment, Sarcoidosis, or Prolonged Immobilisation.

Eligibility is defined by regulatory authorities primarily by ruling out patients with existing mineral overload or compromised kidney function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents confirm that Calperos D3, due to its calcium and Vitamin D components, has several documented interactions primarily affecting drug absorption or increasing the risk of hypercalcaemia. These interactions require either mandated dose separation or close clinical monitoring.

Interactions Requiring Close Monitoring (Pharmacodynamic Risk)

Cardiac Glycosides (e.g., Digoxin): Concomitant use increases the risk of cardiac dysrhythmia due to the potential for hypercalcaemia. Monitoring of ECG and serum calcium levels is required.
Thiazide Diuretics: These medicines reduce calcium excretion, significantly increasing the risk of hypercalcaemia. Regular monitoring of plasma calcium levels is necessary.
Anticonvulsants (e.g., Phenytoin): These can accelerate the metabolism of Vitamin D, which may reduce its overall efficacy.

Interactions Requiring Timing Separation (Absorption Interference)

Calcium carbonate can impair the absorption of certain medicines, necessitating specific timing rules outlined in the prescribing information to maintain the efficacy of the co-administered drug.

Interacting Substance	Required Timing Separation
Tetracycline Antibiotics	At least 2 hours before or 4–6 hours after Calperos D3.
Levothyroxine	Administer at least 4 hours apart.
Bisphosphonates	Administer at least 1 hour before Calperos D3.

Interactions with Food and Supplements

Foods rich in oxalic acid (e.g., spinach, rhubarb) or phytic acid (e.g., whole cereals) are documented to inhibit calcium absorption. The regulatory documentation advises avoiding these foods within two hours of taking Calperos D3. Co-administration with other calcium or Vitamin D supplements increases the risk of hypercalcaemia and is generally reserved for use under professional guidance.

Mechanism of Action

Calperos D3 delivers calcium carbonate and cholecalciferol (Vitamin D3) for systemic modulation of calcium homeostasis. In the stomach, calcium carbonate dissociates into absorbable Ca^2+ ions. Cholecalciferol, a secosteroid prohormone, undergoes successive hydroxylation, first in the liver by 25-hydroxylase to form calcifediol (25-hydroxyvitamin D3), and then primarily in the kidney by 1-alpha-hydroxylase to form the biologically active metabolite, calcitriol (1,25-dihydroxyvitamin D3).

Calcitriol acts as a nuclear receptor agonist, binding to the Vitamin D Receptor (VDR), which then forms a heterodimer with the Retinoic X Receptor (RXR). This complex translocates to the nucleus to act as a transcription factor, modulating the expression of target genes. In the small intestine, this pathway increases the synthesis of calcium-binding proteins, such as calbindin, which enhances the active transport and passive diffusion of Ca^2+ across the enterocyte brush border.

The resulting increase in circulating Ca^2+ ions provides substrate for bone mineralization and modulates parathyroid hormone (PTH) secretion through a negative feedback loop at the parathyroid gland, thereby regulating systemic Ca^2+ and phosphate flux.

Dosage and Administration Information

Instruction Map: How to use Calperos D3

This map details the instructions for using Calperos D3.

Administration Scope

Property	Instruction
Route of administration	Oral use via the mouth, consistent with the chewable tablet form.
Dosing schedule	The standard regimen for adults and the elderly is one tablet taken twice per day, which supplies a total of 1000 mg elemental calcium and 800 IU Vitamin D3 daily.
Timing in relation to meals	Intake must be separated by at least two hours from meals containing high levels of oxalic acid (e.g., spinach) or phytic acid (e.g., whole cereals).
Preparation requirements	The tablet must be fully chewed before swallowing.
Age-group administration rules	Use for pregnant or lactating women requires a dose reduction to one tablet per day.
Missed-dose rules	If a dose is missed, the patient must not take a double dose but should leave the forgotten dose out entirely.
Special procedural conditions	The timing of intake must be separated from certain co-administered medications like tetracyclines or bisphosphonates to maintain proper absorption.

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Oral, requiring physical preparation via chewing.
Frequency pattern	Divided-dose daily (twice per day), generally for long-term use.
Standardization basis	Based on standardized clinical guidelines for mineral and vitamin supplementation.
Use-context constraints	Administration is constrained by dietary composition and the timing of other co-administered medications.

Resulting Procedural Structure

Step sequence:

The tablet must be fully chewed.
The dose must be taken twice per day according to the standard regimen.
The administration must be timed to avoid conflicts with meals high in specific acids or co-administered drugs.

Connection to the overall use protocol: The administration protocol mandates the oral route with a specific chewing preparation step to ensure the dual active ingredients are released correctly. The divided-dose frequency and the time-separation rules establish the necessary kinetic conditions for the sustained availability and absorption of both elemental calcium and cholecalciferol, defining the standardized approach to usage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calperos D3

Evidence for the Prevention and Treatment of Combined Calcium and Vitamin D Deficiency

The evidence base for this combination product was evaluated in research exploring nutritional shortfalls, often using a framework of "well-established medicinal use." This research primarily relies on Systematic Reviews and Meta-analyses that synthesize findings across many studies, rather than new, large-scale clinical trials. Studies have primarily been conducted on older adults and groups at high risk of deficiency, such as institutionalized or housebound individuals.

Researchers in these studies have mainly focused on biomarkers, which are measurements taken in the body that reflect measurements of a physiological state. Studies examined how the combination product was associated with serum levels of Vitamin D (25(OH)D) and serum calcium. Findings describe patterns observed over short-term periods (typically 3 to 6 months) where the combination was associated with changes in these biomarker levels. This evidence contributes to the broader evidence landscape related to mineral homeostasis in people with existing deficiencies.

Evidence for Adjunctive Use with Osteoporosis Treatments

Research has explored the use of this combination product in trials alongside primary anti-osteoporosis treatments in Randomized Controlled Trials (RCTs) and subsequent large-scale Meta-analyses. These trials have focused on populations with a heightened risk of bone loss and fractures, notably postmenopausal women and older adults.

A focus of the research was the observation of skeletal structure changes over time. Key outcomes studied included changes in Bone Mineral Density (BMD), as well as the recording of clinical events, specifically the incidence of new fractures. Long-term RCTs examined whether the combination, when used in trials alongside primary osteoporosis drugs, was associated with patterns in fracture incidence and BMD changes.

Research Gaps and Remaining Uncertainties

One key limitation is the debate surrounding the necessity of the calcium component for patients who are not calcium-deficient, which contributes to the mixed findings on outcomes compared to Vitamin D alone for fracture incidence. Furthermore, follow-up durations were limited in some key studies that only measured biomarkers, meaning long-term effects are not fully established beyond the trial periods. The data show patterns related to specific conditions, but findings describe group patterns, not personal outcomes, and evidence for certain subgroups remains uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Calperos D3 (FAQ)

Q: How quickly should Calperos D3 start working?

Official information indicates that the product is intended for long-term use. Changes to important biomarkers, such as serum calcium and Vitamin D levels, are generally observed over several weeks or months of continuous administration, reflecting the long-term nature of mineral restoration.

Q: Is it common to feel a mild stomach upset when starting Calperos D3?

Official safety documents list certain gastrointestinal effects, such as nausea or flatulence, as rare adverse reactions (affecting 1 to 10 users in 10,000). This means such effects are not commonly expected. Uncommon or severe effects should be reviewed with a healthcare provider.

Q: Is there a recommended time of day (morning or evening) to take Calperos D3?

Regulatory guidelines state that the product should be taken as a divided dose, typically twice per day. Official instructions prioritize separating the intake from certain foods and other co-administered medicines, but they do not specify an optimal time of day, such as morning versus evening.

Q: What do official health organizations say about the evidence for Calperos D3?

Government-run health organizations and official prescribing information acknowledge the therapeutic role of this type of combination product in addressing simultaneous calcium and Vitamin D shortfalls. The evidence themes are summarized in the product's regulatory documents, focusing on use in deficiency and as an adjunct to primary treatments.

Q: Why might a healthcare professional suggest this product instead of a cheaper supplement?

The product is officially classified as a fixed-dose combination medicine intended for a well-established medicinal use in correcting combined shortfalls. This classification differentiates it from single-ingredient dietary supplements.

Q: Does Calperos D3 need to be taken consistently to see results?

The established regulatory regimen supports long-term, sustained administration. Research that supports the use of Calperos D3 is based on continuous daily administration, which is typically necessary to achieve and maintain stable mineral levels in the body over time.

Q: What are the patient-perceivable signs of a possible interaction with Calperos D3?

Interactions with other medicines typically involve reduced absorption of the co-administered drug or an increased risk of hypercalcaemia (excessive calcium in the blood). Signs of hypercalcaemia, as noted in official documents, can include physical symptoms such as nausea, vomiting, or feeling excessively thirsty.

Q: How long is a typical course of treatment with Calperos D3?

Regulatory information indicates that Calperos D3 is intended for long-term use. This aligns with its role in managing chronic conditions such as combined calcium and Vitamin D deficiency and its function as an adjunctive treatment for osteoporosis.

Q: Can Calperos D3 be taken with multivitamins?

Official product information advises that taking Calperos D3 with other sources of calcium or Vitamin D, which are often found in multivitamins, can increase the risk of hypercalcaemia. To manage the risk of hypercalcaemia, co-administration with other supplements should be reviewed by a healthcare professional.

Q: Does Calperos D3 help with muscle cramps?

The product's intended action supports stable serum calcium levels, which are physiologically necessary for healthy nerve and muscle signaling. However, official regulatory documents do not list the treatment of muscle cramps as an official indication for Calperos D3.

Q: Are the research findings on Calperos D3 generally positive?

Official summaries of the research indicate that studies confirm the expected effect of the product on biomarkers (measurements of mineral levels). However, regulatory summaries often note that the findings regarding clinical outcomes, such as fracture reduction when compared to Vitamin D alone, have been mixed.

Q: Does Calperos D3 require a prescription from a doctor?

The regulatory classification of this medicine can vary by country and by the specific dosage strength of the formulation. The product is generally classified as a Prescription Only Medicine (POM) or subject to controlled availability by a pharmacist in many regions.

Q: Can Calperos D3 be taken by people with lactose intolerance?

Regulatory documents, such as the Patient Information Leaflet, are required to list all inactive ingredients, or excipients, used in the tablet's formulation. This disclosure includes details on whether ingredients like lactose are present in the product.

Q: Is Calperos D3 gluten-free?

Official regulatory summaries must state if the product contains any excipients, or inactive ingredients, that are derived from cereals containing gluten. If the substance is not listed as an ingredient, the product is generally considered to be gluten-free according to labeling standards.

Q: Does Calperos D3 contain any sugar or sweeteners?

Because this is a chewable tablet, specific inactive ingredients, such as sucrose or sorbitol and other sweeteners, are typically included in the formulation. Official product documents are required to list these components in the excipient section.

Q: Can Calperos D3 cause a dry mouth?

Official safety information and adverse reaction summaries are comprehensive records of effects reported during trials and post-marketing surveillance. These regulatory documents do not commonly list dry mouth as a reported side effect for this product class.

Q: Can I stop taking Calperos D3 suddenly?

Calperos D3 is intended for long-term use to manage specific mineral shortfalls, and official documentation does not contain any specific regulatory warnings regarding withdrawal symptoms if stopped suddenly. However, any decision to discontinue treatment should be reviewed by a healthcare professional.

Q: What are the inactive ingredients in Calperos D3?

Official product information, typically found in the Summary of Product Characteristics or Patient Information Leaflet, is required to list all inactive ingredients (excipients). These components include the binding agents, fillers, and flavorings necessary to create the final chewable tablet formulation.

Q: Does Calperos D3 come in different strengths or formulations?

Regulatory product databases confirm that the medicine is marketed in various regulated dosage strengths across different regions. For example, different formulations are available that provide varying amounts of elemental calcium and Vitamin D3 under the same or similar product name.

How should Calperos D3 be stored and disposed of?

Official Storage and Disposal Requirements

To ensure the stability of the active ingredients, Calperos D3 chewable tablets must be stored according to regulatory requirements for temperature and environmental protection.

Condition	Requirement
Temperature Limit	Do not store the medicine above 25 C (seventy-seven degrees Fahrenheit).
Protection	Keep the product in its original, tightly closed container to protect it from moisture and light.
Child Safety	The medicine must be kept strictly out of the sight and reach of children.
Disposal	Any unused or expired medicine must be disposed of in accordance with local and national regulations for pharmaceutical waste.

The official label mandates that the product remains in its specific packaging to preserve the stability of the cholecalciferol component. Final disposal must be done via approved channels, not through household waste or wastewater.

Calperos D3